Literature DB >> 33539584

Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.

Gaurav Goyal1,2, Jithma P Abeykoon3, Marie Hu4, Jason R Young5, Mithun V Shah3, N Nora Bennani3, Timothy G Call3, C Christopher Hook3, Animesh Pardanani3, David J Inwards3, Robert Vassallo6, Jay H Ryu6, W Oliver Tobin7, Matthew J Koster8, Caroline J Davidge-Pitts9, Aishwarya Ravindran10, Karen L Rech10, Ronald S Go4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539584      PMCID: PMC8044045          DOI: 10.1002/ajh.26119

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  14 in total

1.  Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.

Authors:  Antonious Z Hazim; Gordon J Ruan; Aishwarya Ravindran; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Oncologist       Date:  2020-10-12

2.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

3.  Cladribine activity in adult langerhans-cell histiocytosis.

Authors:  A Saven; C Burian
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

4.  Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.

Authors:  Antoine Néel; Mathieu Artifoni; Anne-Maelle Fontenoy; Benoit Tessoulin; Gwenaël Lorillon; Fleur Cohen-Aubart; Julien Haroche; Thierry Genereau; Mathilde de Menthon; Loïc Guillevin; Hélène Maillard; Jean-Emmanuel Kahn; Olivier Hermine; Carla Araujo; Claire Dromer; Denis Jullien; Mohamed Hamidou; Jean Donadieu; Abdellatif Tazi
Journal:  Br J Haematol       Date:  2020-03-19       Impact factor: 6.998

5.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397

6.  2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis.

Authors:  Animesh Pardanani; Robert L Phyliky; Chin-Yang Li; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2003-03       Impact factor: 7.616

7.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

8.  Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis.

Authors:  Vincent Grobost; Chahera Khouatra; Romain Lazor; Jean-François Cordier; Vincent Cottin
Journal:  Orphanet J Rare Dis       Date:  2014-11-30       Impact factor: 4.123

9.  Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Gary A Ulaner; Esther Drill; Justin Buthorn; Michelle Ki; Lillian Bitner; Hana Cho; Robert J Young; Jasmine H Francis; Raajit Rampal; Mario Lacouture; Lynn A Brody; Neval Ozkaya; Ahmet Dogan; Neal Rosen; Alexia Iasonos; Omar Abdel-Wahab; David M Hyman
Journal:  Nature       Date:  2019-03-13       Impact factor: 49.962

10.  Optimal therapy for adults with Langerhans cell histiocytosis bone lesions.

Authors:  Maria A Cantu; Philip J Lupo; Mrinalini Bilgi; M John Hicks; Carl E Allen; Kenneth L McClain
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more
  3 in total

Review 1.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

Review 2.  Adult Langerhans Cell Histiocytosis and the Skeleton.

Authors:  Danae Georgakopoulou; Athanasios D Anastasilakis; Polyzois Makras
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

3.  ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.

Authors:  Paul G Kemps; Jennifer Picarsic; Benjamin H Durham; Zofia Hélias-Rodzewicz; Laura Hiemcke-Jiwa; Cor van den Bos; Marianne D van de Wetering; Carel J M van Noesel; Jan A M van Laar; Robert M Verdijk; Uta E Flucke; Pancras C W Hogendoorn; F J Sherida H Woei-A-Jin; Raf Sciot; Andreas Beilken; Friedrich Feuerhake; Martin Ebinger; Robert Möhle; Falko Fend; Antje Bornemann; Verena Wiegering; Karen Ernestus; Tina Méry; Olga Gryniewicz-Kwiatkowska; Bozenna Dembowska-Baginska; Dmitry A Evseev; Vsevolod Potapenko; Vadim V Baykov; Stefania Gaspari; Sabrina Rossi; Marco Gessi; Gianpiero Tamburrini; Sébastien Héritier; Jean Donadieu; Jacinthe Bonneau-Lagacherie; Claire Lamaison; Laure Farnault; Sylvie Fraitag; Marie-Laure Jullié; Julien Haroche; Matthew Collin; Jackie Allotey; Majid Madni; Kerry Turner; Susan Picton; Pasquale M Barbaro; Alysa Poulin; Ingrid S Tam; Dina El Demellawy; Brianna Empringham; James A Whitlock; Aditya Raghunathan; Amy A Swanson; Mariko Suchi; Jon M Brandt; Nabeel R Yaseen; Joanna L Weinstein; Irem Eldem; Bryan A Sisk; Vaishnavi Sridhar; Mandy Atkinson; Lucas R Massoth; Jason L Hornick; Sanda Alexandrescu; Kee Kiat Yeo; Kseniya Petrova-Drus; Stephen Z Peeke; Laura S Muñoz-Arcos; Daniel G Leino; David D Grier; Robert Lorsbach; Somak Roy; Ashish R Kumar; Shipra Garg; Nishant Tiwari; Kristian T Schafernak; Michael M Henry; Astrid G S van Halteren; Oussama Abla; Eli L Diamond; Jean-François Emile
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.